GPR30 predicts poor survival for ovarian cancer

Harriet O. Smith, Hugo Arias-Pulido, Dennis Yi-Shin Kuo, Tamara Howard, Clifford R. Qualls, Sang Joon Lee, Claire F. Verschraegen, Helen J. Hathaway, Nancy E. Joste, Eric R. Prossnitz

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Objectives: GPR30 is a 7-transmembrane G protein-coupled estrogen receptor that functions alongside traditional estrogen receptors to regulate cellular responses to estrogen. Recent studies suggest that GPR30 expression is linked to lower survival rates in endometrial and breast cancer. This study was conducted to evaluate GPR30 expression in ovarian tumors. Methods: GPR30 expression was analyzed using immunohistochemistry and archival specimens from 45 patients with ovarian tumors of low malignant potential (LMP) and 89 patients with epithelial ovarian cancer (EOC). Expression, defined as above or below the median (intensity times the percentage of positive epithelial cells) was correlated with predictors of adverse outcome and survival. Results: GPR30 expression above the median was observed more frequently in EOC than in LMP tumors (48.3% vs. 20%, p = 0.002), and in EOC was associated with lower 5-year survival rates (44.2% vs. 82.6%, Log-rank p < 0.001). Tumor grade and FIGO stage, the other significant predictors of survival, were used to stratify cases into "high risk" and "low risk" groups. The 5-year survival rate for "low risk" EOC (all grade 1 and Stage I/II, grade 2) was 100%. In "high risk" EOC (all grade 3 and Stage III/IV, grade 2), the difference in 5-year survival by GPR 30 expression was significant (33.3% vs. 72.4%, p = 0.001). Conclusions: The novel estrogen-responsive receptor GPR30 is preferentially expressed in "high risk" EOC and is associated with lower survival rates. Further investigation of GPR30 as a potential target for therapeutic intervention in high risk EOC is warranted.

Original languageEnglish (US)
Pages (from-to)465-471
Number of pages7
JournalGynecologic Oncology
Volume114
Issue number3
DOIs
StatePublished - Sep 2009

Fingerprint

Ovarian Neoplasms
Survival
Survival Rate
Estrogen Receptors
Neoplasms
Endometrial Neoplasms
G-Protein-Coupled Receptors
Ovarian epithelial cancer
Estrogens
Epithelial Cells
Immunohistochemistry
Breast Neoplasms

Keywords

  • Epithelial ovarian carcinoma
  • GPR30
  • Low malignant potential
  • Overall survival

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Smith, H. O., Arias-Pulido, H., Kuo, D. Y-S., Howard, T., Qualls, C. R., Lee, S. J., ... Prossnitz, E. R. (2009). GPR30 predicts poor survival for ovarian cancer. Gynecologic Oncology, 114(3), 465-471. https://doi.org/10.1016/j.ygyno.2009.05.015

GPR30 predicts poor survival for ovarian cancer. / Smith, Harriet O.; Arias-Pulido, Hugo; Kuo, Dennis Yi-Shin; Howard, Tamara; Qualls, Clifford R.; Lee, Sang Joon; Verschraegen, Claire F.; Hathaway, Helen J.; Joste, Nancy E.; Prossnitz, Eric R.

In: Gynecologic Oncology, Vol. 114, No. 3, 09.2009, p. 465-471.

Research output: Contribution to journalArticle

Smith, HO, Arias-Pulido, H, Kuo, DY-S, Howard, T, Qualls, CR, Lee, SJ, Verschraegen, CF, Hathaway, HJ, Joste, NE & Prossnitz, ER 2009, 'GPR30 predicts poor survival for ovarian cancer', Gynecologic Oncology, vol. 114, no. 3, pp. 465-471. https://doi.org/10.1016/j.ygyno.2009.05.015
Smith, Harriet O. ; Arias-Pulido, Hugo ; Kuo, Dennis Yi-Shin ; Howard, Tamara ; Qualls, Clifford R. ; Lee, Sang Joon ; Verschraegen, Claire F. ; Hathaway, Helen J. ; Joste, Nancy E. ; Prossnitz, Eric R. / GPR30 predicts poor survival for ovarian cancer. In: Gynecologic Oncology. 2009 ; Vol. 114, No. 3. pp. 465-471.
@article{726004c1e00548bc9e7d7403b4c368c5,
title = "GPR30 predicts poor survival for ovarian cancer",
abstract = "Objectives: GPR30 is a 7-transmembrane G protein-coupled estrogen receptor that functions alongside traditional estrogen receptors to regulate cellular responses to estrogen. Recent studies suggest that GPR30 expression is linked to lower survival rates in endometrial and breast cancer. This study was conducted to evaluate GPR30 expression in ovarian tumors. Methods: GPR30 expression was analyzed using immunohistochemistry and archival specimens from 45 patients with ovarian tumors of low malignant potential (LMP) and 89 patients with epithelial ovarian cancer (EOC). Expression, defined as above or below the median (intensity times the percentage of positive epithelial cells) was correlated with predictors of adverse outcome and survival. Results: GPR30 expression above the median was observed more frequently in EOC than in LMP tumors (48.3{\%} vs. 20{\%}, p = 0.002), and in EOC was associated with lower 5-year survival rates (44.2{\%} vs. 82.6{\%}, Log-rank p < 0.001). Tumor grade and FIGO stage, the other significant predictors of survival, were used to stratify cases into {"}high risk{"} and {"}low risk{"} groups. The 5-year survival rate for {"}low risk{"} EOC (all grade 1 and Stage I/II, grade 2) was 100{\%}. In {"}high risk{"} EOC (all grade 3 and Stage III/IV, grade 2), the difference in 5-year survival by GPR 30 expression was significant (33.3{\%} vs. 72.4{\%}, p = 0.001). Conclusions: The novel estrogen-responsive receptor GPR30 is preferentially expressed in {"}high risk{"} EOC and is associated with lower survival rates. Further investigation of GPR30 as a potential target for therapeutic intervention in high risk EOC is warranted.",
keywords = "Epithelial ovarian carcinoma, GPR30, Low malignant potential, Overall survival",
author = "Smith, {Harriet O.} and Hugo Arias-Pulido and Kuo, {Dennis Yi-Shin} and Tamara Howard and Qualls, {Clifford R.} and Lee, {Sang Joon} and Verschraegen, {Claire F.} and Hathaway, {Helen J.} and Joste, {Nancy E.} and Prossnitz, {Eric R.}",
year = "2009",
month = "9",
doi = "10.1016/j.ygyno.2009.05.015",
language = "English (US)",
volume = "114",
pages = "465--471",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - GPR30 predicts poor survival for ovarian cancer

AU - Smith, Harriet O.

AU - Arias-Pulido, Hugo

AU - Kuo, Dennis Yi-Shin

AU - Howard, Tamara

AU - Qualls, Clifford R.

AU - Lee, Sang Joon

AU - Verschraegen, Claire F.

AU - Hathaway, Helen J.

AU - Joste, Nancy E.

AU - Prossnitz, Eric R.

PY - 2009/9

Y1 - 2009/9

N2 - Objectives: GPR30 is a 7-transmembrane G protein-coupled estrogen receptor that functions alongside traditional estrogen receptors to regulate cellular responses to estrogen. Recent studies suggest that GPR30 expression is linked to lower survival rates in endometrial and breast cancer. This study was conducted to evaluate GPR30 expression in ovarian tumors. Methods: GPR30 expression was analyzed using immunohistochemistry and archival specimens from 45 patients with ovarian tumors of low malignant potential (LMP) and 89 patients with epithelial ovarian cancer (EOC). Expression, defined as above or below the median (intensity times the percentage of positive epithelial cells) was correlated with predictors of adverse outcome and survival. Results: GPR30 expression above the median was observed more frequently in EOC than in LMP tumors (48.3% vs. 20%, p = 0.002), and in EOC was associated with lower 5-year survival rates (44.2% vs. 82.6%, Log-rank p < 0.001). Tumor grade and FIGO stage, the other significant predictors of survival, were used to stratify cases into "high risk" and "low risk" groups. The 5-year survival rate for "low risk" EOC (all grade 1 and Stage I/II, grade 2) was 100%. In "high risk" EOC (all grade 3 and Stage III/IV, grade 2), the difference in 5-year survival by GPR 30 expression was significant (33.3% vs. 72.4%, p = 0.001). Conclusions: The novel estrogen-responsive receptor GPR30 is preferentially expressed in "high risk" EOC and is associated with lower survival rates. Further investigation of GPR30 as a potential target for therapeutic intervention in high risk EOC is warranted.

AB - Objectives: GPR30 is a 7-transmembrane G protein-coupled estrogen receptor that functions alongside traditional estrogen receptors to regulate cellular responses to estrogen. Recent studies suggest that GPR30 expression is linked to lower survival rates in endometrial and breast cancer. This study was conducted to evaluate GPR30 expression in ovarian tumors. Methods: GPR30 expression was analyzed using immunohistochemistry and archival specimens from 45 patients with ovarian tumors of low malignant potential (LMP) and 89 patients with epithelial ovarian cancer (EOC). Expression, defined as above or below the median (intensity times the percentage of positive epithelial cells) was correlated with predictors of adverse outcome and survival. Results: GPR30 expression above the median was observed more frequently in EOC than in LMP tumors (48.3% vs. 20%, p = 0.002), and in EOC was associated with lower 5-year survival rates (44.2% vs. 82.6%, Log-rank p < 0.001). Tumor grade and FIGO stage, the other significant predictors of survival, were used to stratify cases into "high risk" and "low risk" groups. The 5-year survival rate for "low risk" EOC (all grade 1 and Stage I/II, grade 2) was 100%. In "high risk" EOC (all grade 3 and Stage III/IV, grade 2), the difference in 5-year survival by GPR 30 expression was significant (33.3% vs. 72.4%, p = 0.001). Conclusions: The novel estrogen-responsive receptor GPR30 is preferentially expressed in "high risk" EOC and is associated with lower survival rates. Further investigation of GPR30 as a potential target for therapeutic intervention in high risk EOC is warranted.

KW - Epithelial ovarian carcinoma

KW - GPR30

KW - Low malignant potential

KW - Overall survival

UR - http://www.scopus.com/inward/record.url?scp=67749119671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67749119671&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2009.05.015

DO - 10.1016/j.ygyno.2009.05.015

M3 - Article

VL - 114

SP - 465

EP - 471

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -